BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 26181017)

  • 21. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
    Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
    Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does my patient with a serum monoclonal spike have multiple myeloma?
    Bianchi G; Ghobrial IM
    Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
    El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
    Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
    Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
    Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance.
    Berenson JR; Yellin O; Quiery A; Brady J; Patel R; Wong SF; Colbourn D; Gravenor D; Tiffany N; Shamasunder HK; Waterman B; Melamed K; Wirtschafter E
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):336-41. PubMed ID: 21816371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fracture risk in monoclonal gammopathy of undetermined significance.
    Melton LJ; Rajkumar SV; Khosla S; Achenbach SJ; Oberg AL; Kyle RA
    J Bone Miner Res; 2004 Jan; 19(1):25-30. PubMed ID: 14753733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
    Berenson JR; Yellin O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
    Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
    Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
    Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
    Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
    [No Abstract]   [Full Text] [Related]  

  • 35. Multimorbidity in patients with monoclonal gammopathy of undetermined significance.
    Epstein MM; Zhou Y; Castaneda-Avila MA; Cohen HJ
    Int J Cancer; 2023 Jun; 152(12):2485-2492. PubMed ID: 36799553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
    Madan S; Greipp PR
    Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
    Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
    Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.
    Turesson I; Kovalchik SA; Pfeiffer RM; Kristinsson SY; Goldin LR; Drayson MT; Landgren O
    Blood; 2014 Jan; 123(3):338-45. PubMed ID: 24222331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.
    Klincová M; Sandecká V; Mikuláiová A; Radocha J; Maisnar V; Hájek R
    Klin Onkol; 2011; 24 Suppl():S14-7. PubMed ID: 21923058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.